

Defibrotide Sodium

AHFS 20:12.92

Products — Defibrotide sodium is available as an 80-mg/mL concentrate for injection in vials containing 2.5 mL of solution; vials contain no preservative and are intended for single-patient use. (3148) Each mL of solution also contains sodium citrate 10 mg in water for injection. (3148) Hydrochloric acid and/or sodium hydroxide may have been added to adjust the pH. (3148)

Defibrotide sodium concentrate for injection must be diluted prior to administration. (3148) The appropriate volume of the concentrate should be withdrawn from the vial and transferred to an infusion bag containing dextrose 5% or sodium chloride 0.9%. (3148) The diluted solution for infusion should be gently mixed and should have a final concentration of 4 to 20 mg/mL. (3148)

pH — Defibrotide sodium concentrate for injection has a pH ranging from 6.8 to 7.8. (3148)

Trade Name(s) — Defitelio.

Administration — Defibrotide sodium is administered intravenously as an infusion over 2 hours after dilution in dextrose 5% or sodium chloride 0.9%. (3148) The final diluted solution for infusion should be administered through an infusion set containing a 0.2- μ m inline

filter. (3148) The intravenous infusion line being used to administer defibrotide sodium should be flushed with dextrose 5% or sodium chloride 0.9% immediately prior to and following administration of the drug. (3148)

Stability — Intact vials of defibrotide sodium should be stored at controlled room temperature. (3148) Defibrotide sodium concentrate for injection is a clear, light yellow to brown solution; the diluted solution for infusion may vary from colorless to light yellow, depending upon the diluent and the final concentration of the drug in the solution. (3148) The diluted solution for infusion should be visually inspected for particulate matter and discoloration prior to administration; only clear solutions without visible particulates should be used. (3148)

The manufacturer states that diluted solutions for infusion should be used within 4 hours if stored at room temperature or 24 hours if stored under refrigeration. (3148)

Vials are intended for single-patient use only. (3148) The manufacturer states that up to 4 doses of the diluted solution for infusion may be prepared at one time if refrigerated. (3148) Partially used vials should be discarded. (3148)

Filtration — Defibrotide solution diluted for infusion should be administered through an infusion set containing a 0.2- μ m inline filter. (3148)

Compatibility Information

Solution Compatibility

Defibrotide sodium

Solution	Mfr	Mfr	Conc/L	Remarks	Ref	C/I
Dextrose 5%		JAZ	4 to 20 g	Use within 4 hr at room temperature or 24 hr under refrigeration	3148	C
Sodium chloride 0.9%		JAZ	4 to 20 g	Use within 4 hr at room temperature or 24 hr under refrigeration	3148	C

Y-Site Injection Compatibility (1:1 Mixture)

Defibrotide sodium

Drug	Mfr	Conc	Mfr	Conc	Remarks	Ref	C/I
Acetaminophen	BRN	10 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Acyclovir sodium	MYL	10 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Albumin human	LFB	200 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Amikacin sulfate	MYL	5 mg/mL ^b	JAZ	8 mg/mL ^b	Solution became milky white, opaque or opalescent	3149	I
Amoxicillin sodium	PAN	40 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Amphotericin B liposomal	GIL	2 mg/mL ^a	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C

Y-Site Injection Compatibility (1:1 Mixture) (Cont.)

Defibrotide sodium							
<i>Drug</i>	<i>Mfr</i>	<i>Conc</i>	<i>Mfr</i>	<i>Conc</i>	<i>Remarks</i>	<i>Ref</i>	<i>C/I</i>
Caspofungin acetate	MCD	0.4 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Ceftazidime	PAN	80 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Ceftriaxone sodium	PAN	100 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Ciprofloxacin	FRK	2 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Clonazepam	RC	0.02 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Clonidine HCl	BI	2.4 mcg/mL ^a	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Cyclosporine	NVA	1.27 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Deferoxamine mesylate	NVA	6.7 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Fluconazole	FRK	2 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Foscarnet sodium	NVX	24 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Furosemide	REN	10 mg/mL	JAZ	8 mg/mL ^b	Slight and transient bubbling occurs only when defibrotide added to furosemide; not observed when order of mixing was reversed	3149	?
Ganciclovir sodium	RC	10 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Heparin sodium	SAA	373 units/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Hydrocortisone sodium succinate	UP	1.9 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Hydroxyzine HCl	REN	0.79 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Imipenem–cilastatin sodium	PAN	9.94 mg/mL ^{b,c}	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Mesna	BA	4.76 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Methylprednisolone sodium succinate	MYL	10 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Metronidazole	BRN	5 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Midazolam HCl	PAN	5 mg/mL	JAZ	8 mg/mL ^b	A fine and transient suspension forms within 2.5 hr only when midazolam HCl added to defibrotide; not observed when order of mixing was reversed	3149	?
Mycophenolate mofetil HCl	RC	11.9 mg/mL ^a	JAZ	8 mg/mL ^b	Solution became milky white and opaque	3149	I
Nalbuphine HCl	MYL	2 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C

Y-Site Injection Compatibility (1:1 Mixture) (Cont.)

Defibrotide sodium

<i>Drug</i>	<i>Mfr</i>	<i>Conc</i>	<i>Mfr</i>	<i>Conc</i>	<i>Remarks</i>	<i>Ref</i>	<i>C/I</i>
Naloxone HCl	MYL	0.4 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Nicardipine HCl	AGT	0.5 mg/mL ^b	JAZ	8 mg/mL ^b	Small particles form in 4 hr	3149	I
Ondansetron HCl	ACD	0.16 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Pantoprazole sodium	TAK	1.6 mg/mL ^b	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Teicoplanin	SAA	125 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Tobramycin sulfate	ERM	10 mg/mL	JAZ	8 mg/mL ^b	Solution immediately became milky white, opaque or opalescent; precipitate formed within 2.5 hr	3149	I
Tranexamic acid	SAA	100 mg/mL	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Trimethoprim–sulfamethoxazole	RC	0.64 mg/mL ^{b,d}	JAZ	8 mg/mL ^b	Visually compatible for 4 hr at room temperature	3149	C
Vancomycin HCl	MYL	10.4 mg/mL ^b	JAZ	8 mg/mL ^b	Solution became milky white and opalescent. Precipitate formed within 1 hr when defibrotide added to vancomycin HCl, but developed immediately when order of mixing was reversed	3149	I

^a*Tested in dextrose 5%.*

^b*Tested in sodium chloride 0.9%.*

^c*Imipenem component. Imipenem in a 1:1 fixed-ratio concentration with cilastatin sodium.*

^d*Trimethoprim component. Trimethoprim in a 1:5 fixed-ratio concentration with sulfamethoxazole.*